Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2024.1369747 Immunology Correction Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease KocheiseLorenz 1 2 * PisedduIgnazio 2 3 VonderlinJoscha 2 4 TjwaEric T. 2 5 BuescherGustav 1 2 MeunierLucy 2 6 GoeggelmannPia 7 FianchiFrancesca 2 8 DumortierJérôme 2 9 BarcielaMar Riveiro 2 10 GeversTom J. G. 2 11 12 Beretta-PiccoliBenedetta Terziroli 2 13 14 15 LondoñoMaria-Carlota 2 16 FrankovaSona 2 17 RoesnerThomas 18 JoergVincent 1 2 SchmidtConstantin 1 2 GlaserFabian 1 2 SutterJan P. 1 2 FründtThorben W. 1 2 LohseAnsgar W. 1 2 HuberSamuel 1 2 von FeldenJohann 1 2 SebodeMarcial 1 2 † SchulzeKornelius 1 2 † 1I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 2European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany 3Department of Medicine II, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany 4Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Berlin, Germany 5Department of Gastroenterology and Hepatology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands 6Service Hépato-Gastro Entérologie, Hôpital St-Eloi, CHU Montpellier, Montpellier, France 7Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany 8CEMAD-Centro Malattie dell’Apparato Digerente, Fondazione Policlinico Universitario Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy 9Service d’hépato-gastroentérologie, Hôpital Edouard Herriot – Hospices civils de Lyon, Université de Lyon, Lyon, France 10Liver Unit, Department of Internal Medicine, Hospital Universitari Valle d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain 11Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, Netherlands 12Nutrim School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands 13Epatocentro Ticino, Lugano, Switzerland 14Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland 15MowatLabs, Faculty of Life Sciences & Medicine, King’s College London, King’s College Hospital, London, United Kingdom 16Liver Unit, Hospital Clinic Barcelona, FCRB-IDIBAPS, CIBEREHD, University of Barcelona, Barcelona, Spain 17Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czechia 18Department of Medical Oncology, National Center of Tumor Diseases (NCT) Heidelberg and Universitätsklinikum Heidelberg, Heidelberg, Germany

Edited and Reviewed by: Pascal Lapierre, University of Montreal Hospital Centre (CRCHUM), Canada

*Correspondence: Lorenz Kocheise, l.kocheise@uke.de

†These authors have contributed equally to this work and share last authorship

 24 01 2024 2024 15 1369747 12 01 2024 15 01 2024 Copyright © 2024 Kocheise, Piseddu, Vonderlin, Tjwa, Buescher, Meunier, Goeggelmann, Fianchi, Dumortier, Barciela, Gevers, Beretta-Piccoli, Londoño, Frankova, Roesner, Joerg, Schmidt, Glaser, Sutter, Fründt, Lohse, Huber, von Felden, Sebode and Schulze 2024 Kocheise, Piseddu, Vonderlin, Tjwa, Buescher, Meunier, Goeggelmann, Fianchi, Dumortier, Barciela, Gevers, Beretta-Piccoli, Londoño, Frankova, Roesner, Joerg, Schmidt, Glaser, Sutter, Fründt, Lohse, Huber, von Felden, Sebode and Schulze

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease by Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Riveiro Barciela M, Gevers TJG, Terziroli Beretta-Piccoli B, Londoño M-C, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M and Schulze K (2024) Front. Immunol. 14:1326078. doi: 10.3389/fimmu.2023.1326078 autoimmune disease (AID) immune checkpoint inhibitors (ICI) autoimmune liver diseases (AILD) immune related adverse effects (irAEs) PD-1/PD-L1 immune checkpoint inhibitors autoimmune hepatitis (AIH) primary sclerosing cholangites (PSC) primary biliary cholangitis (PBC) section-in-acceptance Cancer Immunity and Immunotherapy

In the published article, there was an error in Table 2. The count of monoclonal antibodies used was interchanged during production between the different antibodies. The corrected Table 2 and its caption appear below.

Immune-related adverse events and immunosuppression.

Baseline characteristics Patients, n = 22 (%)
irAE
Grade 1 3 (13.6)
Grade 2 5 (22.7)
None 14 (63.6)
Liver irAE
Grade 1 2 (9.1)
Grade 2 1 (4.5)
Non–Liver irAE
Colitis 1 (4.5)
Pneumonitis 1 (4.5)
Inflammatory arthritis 1 (4.5)
Rash 2 (9.1)
Treatment regimen before ICI#
Mycophenolate mofetil 1 (4.5)
Azathioprine 4 (18.1)
Corticosteroids 2 (9.1)
Methotrexate* 1 (4.5)
UDCA 9 (40.9)
Obeticholic acid 1 (4.5)
No treatment for AILD 7 (31.8)
Treatment adjustment during ICI therapy due to non-liver related events#
Start Hydroxycholoroquine* 1 (4.5)
Start or increase of corticosteroids 2 (9.1)
No change in treatment 16 (72.7)
Treatment adjustment during ICI therapy due to ILICI or AILD#
Start or increase of corticosteroids 2 (9.1)
Start UDCA 1 (4.5)
Change from obeticholic acid to Fenofibrate 1 (4.5)
Stop Azathioprine 1 (4.5)
No change in treatment 16 (72.7)
Monoclonal antibody used
Atezolizumab 7 (31.8)
Durvalumab 5 (22.7)
Pembrolizumab 4 (18.1)
Nivolumab 4 (18.1)
Nivolumab + Ipilimumab 1 (4.5)
Spartalizumab 1 (4.5)

No changes in immunosuppressive therapy were made before commencing ICI treatment to prevent potential irAEs. #Multiple treatments possible *Treatment for Rheumatoid arthritis.

The authors apologize for this error introduced during production and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.